2024 ESMO｜消化道肿瘤重磅研究Oral & Mini Oral前瞻

摘要号及标题：

502O – FFCD 1703 POCHI研究初步结果：帕博利珠单抗+CAPOX+贝伐珠单抗用于微卫星稳定且高免疫浸润的转移性结直肠癌患者

502O – Pembrolizumab in combination with CAPOX and bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: preliminary results of FFCD 1703 POCHI trial

讲者：David Tougeron (Poitiers, France, CEDEX)

讲座时间：08:40 - 08:50

摘要号及标题：

503O – NICHE-3研究：新辅助纳武利尤单抗 + relatlimab用于dMMR结肠癌

503O – Neoadjuvant nivolumab (nivo) plus relatlimab (rela) in MMR-deficient colon cancer: Results of the NICHE-3 study.

讲者：Peter G. De Gooyer (Amsterdam, Netherlands)

讲座时间：09:20 - 09:30

摘要号及标题：

504O – II期IMHOTEP研究：帕博利珠单抗新辅助治疗dMMR/MSI肿瘤的结直肠癌队列结果

504O – IMHOTEP Phase II trial of neoadjuvant pembrolizumab in dMMR/MSI tumors: results of the colorectal cancer cohort

讲者：Christelle De la Fouchardiere (Marseille, Cedex 09, France, CEDEX)

讲座时间：09:30 - 09:40

摘要号及标题：

505O – Ib期CodeBreaK 101研究：索拉托西布 + panitumumab + FOLFIRI一线治疗KRAS G12C突变转移性结直肠癌的安全性和有效性分析

505O – Sotorasib (soto), panitumumab (pani) and FOLFIRI in the first-line (1L) setting for KRAS G12C–mutated metastatic colorectal cancer (mCRC): Safety and efficacy analysis from the phase 1b CodeBreaK 101 study

讲者：Salvatore Siena (Milan, Italy)

讲座时间：15:05 - 15:15

摘要号及标题：

506O - 一项通过AIO和GONO对11项随机试验的分析：评价不可切除转移性结直肠癌一线治疗的疾病进展风险，以指导放射学评估的时间间隔

506O - Evaluation of risk of disease progression in first-line therapy of unresected metastatic colorectal cancer to guide intervals of radiological assessment- an analysis of eleven randomized trials by AIO and GONO.

讲者：Marco M. Germani (Pisa, Italy)

讲座时间：15:45 - 15:55

摘要号及标题：

507MO - LEANOX试验：以去脂体重为基础的奥沙利铂剂量在Ⅲ期结直肠癌辅助治疗中对神经毒性的影响的II期、随机、多中心最终结果

507MO - Impact of lean body mass-based oxaliplatin dosage on neurotoxicity in adjuvant treatment of stage III colorectal cancer. Final results of the phase II randomized multicenter LEANOX trial

讲者：Eric Assenat (Montpellier, Cedex 5, France, CEDEX 5)

讲座时间：14:45 - 14:50

摘要号及标题：

508MO – 随机OPERA研究：早期直肠腺癌的器官保留的5年结果

508MO – Organ preservation in early rectal adenocarcinoma: 5-year results of the randomized opera trial

讲者：Syrine Ben Dhia (Sousse, Tunisia)

讲座时间：15:10 - 15:15

摘要号及标题：

509MO - NO-CUT研究首次结果：非手术治疗的全程新辅助治疗错配修复正常的局部晚期直肠癌患者

509MO - Total Neoadjuvant Treatment (TNT) with Non-Operative Management (NOM) for Proficient Mismatch Repair Locally Advanced Rectal Cancer (pMMR LARC): First Results of NO-CUT Trial

讲者：Alessio Amatu (Milan, Italy)

讲座时间：15:15 - 15:20

摘要号及标题：

510MO - 帕博利珠单抗治疗局限性MSI-H/dMMR实体瘤的长期生存和器官保留

510MO - Long-Term Survival and Organ Preservation with Pembrolizumab in Localized MSI-H/dMMR Solid Tumors

讲者：Kaysia Ludford (Houston, United States of America)

讲座时间：15:20 - 15:25

摘要号及标题：

511MO - 随机Ⅱ期CITRIC研究：西妥昔单抗 + 伊立替康治疗ctDNA选定的转移性结直肠癌患者的三线再挑战

511MO - Third line rechallenge with cetuximab (Cet) and irinotecan in circulating tumor DNA (ctDNA) selected metastatic colorectal cancer (mCRC) patients: the randomized phase II CITRIC trial.

讲者：Cristina Santos Vivas (L'Hospitalet de Llobregat, Spain)

讲座时间：15:40 - 15:45

摘要号及标题：

512MO - SAKK 41/13研究：阿司匹林辅助治疗PIK3CA突变结肠癌患者的Ⅲ期、前瞻性、随机、安慰剂对照、多中心试验

512MO - Adjuvant Aspirin Treatment in PIK3CA Mutated Colon Cancer Patients – The Phase III, Prospective-Randomized Placebo-Controlled Multicenter SAKK 41/13 Trial

讲者：Ulrich Güller (Thun, Switzerland)

讲座时间：15:45 - 15:50

摘要号及标题：

513MO - OrigAMI-1研究：Amivantamab + FOLFOX/FOLFIRI 治疗转移性结直肠癌患者的开放标签、Ib/Ⅱ期试验

513MO - Amivantamab plus FOLFOX or FOLFIRI in metastatic colorectal cancer: Results from OrigAMI-1, an open-label, phase 1b/2 study

讲者：Filippo Pietrantonio (Milan, Italy)

讲座时间：15:50 - 15:55

摘要号及标题：

609O - 一项Ⅰ期研究：靶向CLDN18.2的抗体药物偶联物SHR-A1904用于胃/胃食管结合部癌

609O - CLDN18.2 targeted antibody-drug conjugate (ADC), SHR-A1904, in patients (pts) with gastric/gastroesophageal junction cancer (GC/GEJC): a phase 1 study

讲者：徐瑞华 教授（中山大学肿瘤防治中心）

讲座时间：15:25 - 15:35

摘要号及标题：

1400O - Ⅲ期KEYNOTE-811研究：帕博利珠单抗+曲妥珠单抗和+化疗用于HER2+晚期、不可切除或转移性G/GEJ腺癌的最终总生存结果

1400O - Final overall survival for the phase 3, KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+ advanced, unresectable or metastatic G/GEJ adenocarcinoma

讲者：Yelena Y. Janjigian (New York, United States of America, NY)

讲座时间：09:20 - 09:30

摘要号及标题：

1401O - DESTINY-Gastric03研究：德曲妥珠单抗（T-DXd）单药和联合治疗晚期或转移性HER2阳性（HER2+）食管、胃或胃食管结合部腺癌（GEJA）患者

1401O - Trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2-positive (HER2+) esophageal, gastric or gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03 (DG-03)

讲者：Yelena Y. Janjigian (New York, United States of America, NY)

讲座时间：09:30 - 09:40

摘要号及标题：

1402MO - 一项通过评估胃食管癌的病理缓解情况指导FLOT辅助化疗的国际研究

1402MO - An international study evaluating pathological response to guide adjuvant FLOT chemotherapy in gastroesophageal cancer

讲者：Margaret M. Lee (Box Hill, Australia)

讲座时间：08:40 - 08:45

摘要号及标题：